Market Research Report
Retinoblastoma (Oncology) - Drugs In Development, 2021
|Retinoblastoma (Oncology) - Drugs In Development, 2021|
Published: August 30, 2021
Global Markets Direct
Content info: 84 Pages
Delivery time: 1-2 business days
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinoblastoma - Drugs In Development, 2021, provides an overview of the Retinoblastoma (Oncology) pipeline landscape.Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy and surgery.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinoblastoma - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Retinoblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Retinoblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Retinoblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 3, 3 and 10 respectively.
Retinoblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.